Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | FOXO1 | Q12778 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1243589 | 0.84 | KMT2A (0.47) | KMT2AMEN1GAAKDM4EALDH1A1 | |
| SCHEMBL1243548 | 0.82 | KMT2A (0.59) | KMT2AMEN1GAAKDM4EALDH1A1 | |
| SCHEMBL1243106 | 0.80 | KMT2A (0.57) | KMT2AMEN1GAAKDM4EALDH1A1 | |
| SCHEMBL1243193 | 0.80 | KMT2A (0.61) | KMT2AMEN1GAAKDM4EALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL1242675 | 0.79 | KMT2A (0.61) | KMT2AMEN1GAAKDM4EALDH1A1 | |
| SCHEMBL1243157 | 0.79 | KDM4E (0.56) | KMT2AMEN1GAAKDM4EALDH1A1 | |
| SCHEMBL1242677 | 0.79 | KMT2A (0.60) | KMT2AMEN1GAAKDM4EALDH1A1 | |
| SCHEMBL1241060 | 0.79 | KMT2A (0.57) | KMT2AMEN1GAAKDM4EALDH1A1 | |
| SCHEMBL1242758 | 0.77 | KMT2A (0.57) | KMT2AMEN1GAAKDM4EALDH1A1 | |
| SCHEMBL1243820 | 0.76 | KMT2A (0.54) | KMT2AMEN1GAAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879878-B2 | such as {2-[({[7-(cyclohexylamino)-6-fluoro-4-oxo-1-[(3S)-tetrahydrofuran-3-yl]-1,4-dihydroquinolin-3-yl}carbonyl)amino]ethyl}phosphonic acid, used as platelet aggregation inhibitor and purinergic receptor (P2Y12) inhibitors; therapy for circulatory diseases involving thrombosis via platelet aggregation | ASTELLAS PHARMA INC. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20090124617-A1 | QUINOLONE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-05-14 | — | — | US | disclosed |
| US-7488739-B2 | Quinolone derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-02-10 | — | — | US | disclosed |
| US-20060148806-A1 | Quinolone derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1650192-A1 | QUINOLONE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2006-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124617-A1 | QUINOLONE DERIVATIVE OR SALT THEREOF | THPO, ABL1, GMPS | KMT2A 2659/4885MEN1 2643/4885GAA 1758/4885 |
| US-20060148806-A1 | Quinolone derivative or salt thereof | THPO, ABL1, GMPS | KMT2A 2659/4885MEN1 2643/4885GAA 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.